Opus Genetics Q2 2026: $88.8M Cash and Pipeline Progress, with Key September Data Readout
IRD has more than doubled off its 52-week low of $1.04.
Summary
Opus Genetics reported Q2 2026 financials with $88.8M in cash, funding operations into 2029. The key catalyst is OPGx-BEST1 Cohort 1 topline data expected in the second week of September 2026.
Key Events · Earnings and Guidance · IRD
-
Q2 2026 Financial Results
Cash and equivalents stood at $88.8 million as of June 30, 2026, providing a runway into 2029. The net loss was $8.1 million ($0.08 per share basic), a significant improvement from $73.6 million in Q1 2026, driven by a $7.2 million non-cash gain on warrant remeasurement.
-
OPGx-BEST1 Data Readout Imminent
Cohort 1 topline data from the Phase 1/2 BIRD-1 trial is expected in the second week of September 2026—the nearest major catalyst.
-
OPGx-LCA5 Registrational Trial Progress
Enrollment is complete, and dosing is planned for Q4 2026, with topline data expected by the end of 2027. The trial design is aligned with the FDA.
-
Pipeline Expansion on Track
OPGx-RDH12 is set to enter the clinic in Q4 2026, OPGx-MERTK in Q1 2027, and OPGx-RHO in H2 2027—multiple shots on goal funded by current cash.
Analysis · IRD · Life Sciences
Opus Genetics closed the quarter with $88.8 million in cash, extending its runway into 2029. The net loss narrowed sharply to $8.1 million from $73.6 million in Q1, largely due to a $7.2 million non-cash gain on warrant remeasurement—not an operating cash inflow. The pipeline, however, is the main event: topline data from OPGx-BEST1 Cohort 1 is expected in the second week of September 2026, a near-term catalyst. Enrollment for the OPGx-LCA5 registrational trial is complete, with dosing planned for Q4 2026. Three additional programs are on track to enter the clinic over the next 18 months. With a cash runway that extends past multiple data readouts, the company is well-positioned to execute, though the $62.1 million warrant liability on the balance sheet reflects the share price rise, not new dilution.
At the time of this filing, IRD was trading at $3.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $312.1M. The 52-week trading range was $1.04 to $5.81. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.